Diaminic carbonates, a new class of anti-inflammatory compounds: Their biological characterization and mode of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 1, 1998, Pages 193-200

  Porro, Giuliana ^a   Bertolini, Giorgio ^a   Bonardi, M Antonietta ^a   Giovanetti, Elena ^a,b   Lento, Paola ^a,c   Leoni, Flavio ^a   Modena, Daniela ^a   Pavich, Gianfranco ^a   Marcucci, Fabrizio ^a,d  

^a Italfarmaco SpA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d CEL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DIAMINIC CARBONATE; INTERLEUKIN 1; ITTF 1779; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOTOXICITY; HYDROPHOBICITY; INFLAMMATION; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BUTYLAMINES; CARBONATES; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031978960     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Akira S, Taga T and Kishimoto T (1993) Interleukin-6 in biology and medicine, Adv Immunol 54:1-78.
2. Alzani R, Corti A, Grazioli L, Cozzi E, Ghezzi P and Marcucci F (1993) Suramin induces deoligomerization of human tumor necrosis factor α. J Biol Chem 268: 12526-12529.
3. Andriuoli G, Bossi M, Caramazza I and Zoppetti G (1990) Heparin by alternative routes of administration. Haemostasis 20:suppl. 1, 154-158.
4. Badger AM and Swift BA (1993) Therapeutic activity of SK&F 105685, a novel azaspirane with suppressor-cell inducing activity. Clin Exp Rheumatol 11:suppl. 8, 107-109.
5. Badger AM and Wright CS (1995) SK&F-106615. Macrophage-targeting antiarthritic. Drugs Fut 20:893-896.
6. Bone RC (1993) Gram-negative sepsis: A dilemma of modern medicine. Clin Microbiol Rev 6:57-68.
7. Brennan FM, Maini RN and Feldmann M (1992) TNFα - a pivotal role in rheumatoid arthritis. Br J Rheumatol 31:293-298.
8. Chikanza IC and Fernandes L (1996) The current status and future prospect for biological targeted therapies for rheumatoid arthritis. Exp Opin Invest Drugs 5:819-828.
9. De Duve C, de Barsy T, Poole B, Trouet A, Tulkens P and Van Hoof F (1974) Lysosomotropic agents. Biochem Pharmacol 23:2495-2531.
10. Echtenacher B, Falk W, Maennel D and Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunul 145:3762-3766.
11. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirley E and Ratliff NB (1987) Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 82:447-455.
12. Fowler PD, Shadforth MF, Crook PR and Lawton A (1984) Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: A 6-month comparative study. Ann Rheum Dis 43:200-204.
13. Goldstein JL, Brunschede BY and Brown MS (1975) Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and triton WR1339. J Biol Chem 250:7854-7862.
14. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH and Vassalli P (1987) Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science (Wash DC) 237:1210-1212.
15. Grazioli L, Casero D, Restivo A, Cozzi E and Marcucci F (1994) Tumor necrosis factor-driven formation of disulfide-linked receptor aggregates. J Biol Chem 267: 21172-21178.
16. Han J, Thompson P and Beutler B (1990) Dexamethasone and pentoxyfilline inhibit endotoxin induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172:391-394.
17. Hurvitz D and Hirschhorn K (1965) Suppression of in vitro lymphocyte responses by chloroquine. N Engl J Med 273:23-25.
18. Lee JC, Laydon JT. McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL and Young PR (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (Lond) 372:739-746.
19. Lewis M, Tartaglia LA, Lee A, Bennett SL, Rice GC, Wong GHW, Chen EY and Goeddel DV (1991) Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 88:2830-2834.
20. Lie SO and Schofield B (1973) Inactivation of lysosomal function in normal cultured human fibroblasts by chloroquine. Biochem Pharmacol 23:3109-3114.
21. Mackenzie AH (1983) Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 75:suppl. 1A. 5-10.
22. Mohler KH, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ and Black RA (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature (Lond) 370:218-220.
23. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 177:1675-1680.
24. Nakano Y, Onozuka K, Terada Y, Shinomiya H and Nakano M (1990) Protective effect of recombinant tumor necrosis factor-α in murine salmonellosis. J Immunol 144:1935-1941.
25. Nassar MN, Agha BJ and Digenis GA (1992) Effects of structural variations on the rates of enzymatic and nonenzymatic hydrolysis of carbonates and carbamates esters. J Pharm Sci 81:295-298.
26. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H and Moore GF (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287-1291.
27. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A and Sucher SH (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50:555-563.
28. Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT and Goeddel DV (1992) Biochemical properties of the 75-kDa tumor necrosis factor receptor. J Biol Chem 267:21172-21178.
29. Ruff MR and Gifford GE (1981) Rabbit tumor necrosis factor mechanism of action. Infect Immun 31:380-385.
30. Smith JG, Magee DM, Williams DM and Graybill JR (1990) Tumor necrosis factor-α plays a role in host defense against Histoplasma capsulatum. J Infect Dis 162: 1349-1353.
31. Ten Wolde S, Bredveld FC, Hermans J, Vandenbroucke JP, van de Laar MAFJ, Markusse HM, Janssen M, van den Brink HR and Dijkmans BA (1996) Randomized placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347-352.
32. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF and Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bactaeremia. Nature (Lond) 330:662-664.
33. Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD and Shires GT (1986) Cachetin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med 164:1368-1373.
34. Tsujimoto H, Yip YK and Vilcek J (1985) Tumor necrosis factor: Specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci USA 82:7626-7630.
35. Williams DM, Magee DM, Bonewald LF, Smith JG, Bleicker CA, Byrne GI and Schachter J (1990) A role m vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun 58:1572-1576.
36. Williams M and Summers JB (1994) Septic shock: The continuing challenge for an effective therapy. Exp Opin Invest Drugs 3:1051-1056.